登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688566 证券简称：吉贝尔 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 注："本报告期"指本季度初至本季度末3个月期间，下同。 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 （二） 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 （三） 主要会计数据 ...

Core Insights - Jibeier (688566.SH) reported a steady growth in revenue and profit for the first three quarters of 2025, with revenue reaching 704 million yuan, a year-on-year increase of 9.52%, and net profit attributable to shareholders reaching 197 million yuan, up 12.80% [1] Group 1: Company Performance - The company has completed the Phase III clinical trial for its new antidepressant drug JJH201501 and plans to submit a New Drug Application (NDA) [1] - JJH201501 is developed using a deuterated drug research platform and is designed to have a multi-receptor action mechanism, potentially offering improved pharmacokinetics [1] Group 2: Market Context - There are approximately 95 million depression patients in China, with 30.28% being under 18 years old, indicating a significant market for antidepressant drugs [2] - The global antidepressant market was valued at approximately $14.5 billion in 2022 and is expected to reach $17.6 billion by 2030 [2] Group 3: Clinical Trial Results - JJH201501 demonstrated good safety and tolerability in clinical trials, with lower incidence rates of common adverse reactions compared to the existing drug vortioxetine [3] - The trial results showed that the dropout and permanent discontinuation rates due to adverse reactions in the 10mg and 15mg groups were comparable to the placebo group and lower than the 20mg group of vortioxetine [3] Group 4: Commercialization Strategy - The company is actively promoting the commercialization of JJH201501, leveraging its existing product channels to accelerate market entry [3] - JJH201501's Phase III clinical trials were conducted across over twenty hospitals nationwide, providing a strong foundation for future commercialization efforts [3]